Packing for AstraZeneca trial vaccines. Phot: Vincenzo Pinto/AFP via Getty Images

AstraZeneca announced on Saturday it's resuming its COVID-19 vaccine trials after pausing earlier this week when a participant fell ill.

The state of play: A statement from AstraZeneca says the Medicines Health Regulatory Authority approved the company's vaccine trials through the University of Oxford to continue.

  • AstraZeneca added that it will "continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic."
  • The patient who was negatively impacted by the vaccine reportedly suffered a neurological reaction.
  • Statements from AstraZeneca and Oxford didn’t reveal anything about the status of tests beyond the U.K.

The big picture: A number of coronavirus vaccines are in phase 3 trials, but AstraZeneca remains a frontrunner. The company says it hopes to complete its vaccine by year's end.

Go deeper

Updated 22 hours ago - Health

U.S. coronavirus updates

Expand chart
Data: The COVID Tracking Project; Note: Does not include probable deaths from New York City; Map: Andrew Witherspoon/Axios

New York Gov. Andrew Cuomo said the state will move forward with its own review of coronavirus vaccines even if the Food and Drug Administration approves one or more for distribution and public use.

Why it matters: The motion could sow further public doubt that the federal government could release a vaccine based on political motives rather than safety and efficacy.

Dave Lawler, author of World
Sep 24, 2020 - World

Global coronavirus vaccine initiative launches without U.S. or China

Data: Gavi, The Vaccine Alliance; Map: Naema Ahmed/Axios

A global initiative to ensure equitable distribution of coronavirus vaccines now includes most of the world — but not the U.S., China or Russia.

Why it matters: Assuming one or more vaccines ultimately gain approval, there will be a period of months or even years in which supply lags far behind global demand. The COVAX initiative is an attempt to ensure doses go where they're most needed, rather than simply to countries that can produce or buy them at scale.

Updated 21 hours ago - Health

World coronavirus updates

Expand chart
Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

The number of deaths from COVID-19 surpassed 980,000 worldwide on Thursday.

By the numbers: Globally, more than 32 million million people have tested positive for the novel coronavirus, Johns Hopkins data shows.